文献速递白血病

Gilteritinib通过BCL6介导上调S100A9在急性髓系白血病中的作用

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该研究探讨FLT3-ITD阳性急性髓系白血病(AML)对gilteritinib耐药机制,通过转录组分析和功能验证发现S100A8/A9参与耐药。Gilteritinib在体内外增加S100A8/A9表达并降低游离钙水平,BCL6作为S100A9转录抑制因子,gilteritinib减少BCL6与S100A9启动子结合从而上调S100A9。BCL6药理抑制加速耐药细胞生长,提示S100A9是BCL6功能性靶点,为克服耐药提供潜在策略。

要点

  • Gilteritinib在FLT3-ITD+ AML中上调S100A8/A9表达并降低游离钙水平。
  • BCL6抑制S100A9转录,gilteritinib通过减少BCL6启动子结合上调S100A9。
  • 靶向S100A9或BCL6通路可能增强gilteritinib抗白血病效应。

核心结论

  • Gilteritinib通过BCL6介导上调S100A9,参与FLT3-ITD+ AML对gilteritinib的耐药。

研究设计与样本

  • 研究采用转录组分析和功能验证研究,对象为FLT3-ITD+ AML细胞。

主要发现

  • Gilteritinib在体内外增加FLT3-ITD+ AML细胞S100A8/A9表达并降低游离钙水平。
  • 遗传操作S100A9改变FLT3-ITD+ AML细胞对gilteritinib的敏感性。
  • 转录因子筛选鉴定BCL6为S100A9表达调节因子,gilteritinib减少BCL6与S100A9启动子结合。
  • 药理抑制BCL6加速gilteritinib耐药FLT3-ITD+ AML细胞生长,提示S100A9是BCL6功能性靶点。

临床怎么用

  • S100A9和BCL6可能作为治疗靶点,以增强gilteritinib对FLT3-ITD+ AML的抗白血病效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug resistance and relapse are common challenges in acute myeloid leukemia (AML), particularly in an aggressive subset bearing internal tandem duplications (ITDs) of the FLT3 receptor (FLT3-ITD+). The tyrosine kinase inhibitor gilteritinib is approved for the treatment of relapse/refractory AML with FLT3 mutations, yet resistance to gilteritinib remains a clinical concern, and the underlying mechanisms remain incompletely understood. Using transcriptomic analyses and functional validation studies, we identified the calcium-binding proteins S100A8 and S100A9 (S100A8/A9) as contributors to gilteritinib resistance in FLT3-ITD+ AML. Exposure of FLT3-ITD+ AML cells to gilteritinib increased S100A8/A9 expression in vivo and in vitro and decreased free calcium levels, and genetic manipulation of S100A9 was associated with altered sensitivity to gilteritinib. Using a transcription factor screen, we identified the transcriptional corepressor BCL6, as a regulator of S100A9 expression and found that gilteritinib decreased BCL6 binding to the S100A9 promoter, thereby increasing S100A9 expression. Furthermore, pharmacological inhibition of BCL6 accelerated the growth rate of gilteritinib-resistant FLT3-ITD+ AML cells, suggesting that S100A9 is a functional target of BCL6. These findings shed light on mechanisms of resistance to gilteritinib through regulation of a target that can be therapeutically exploited to enhance the antileukemic effects of gilteritinib.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zavorka Thomas ME, Jeon JY, Talebi Z, et al. Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia. Blood Adv. 2021. PMID: 34614509. doi:10.1182/bloodadvances.2021005614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。